|
at least two companies seem to be in trials with a mAb vs TRAIL receptor 2
one is AMGEN who make denosumab, mAb vs RANKL, who have 5 active trials
A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Phase II, Phase I
20060295
NCT00534027
2.
Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer
Phase II, Phase I
Active
18 and over
20060464
NCT00625651
3.
Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma
Phase II, Phase I
Pharmaceutical / Industry
20060324
NCT00626704
4.
A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer
Phase II, Phase I
20060323
NCT00630552
5.
AMG 655/Panitumumab Combination Metastatic Colorectal Cancer Study
|